Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani , Thomas A. D’Amico , David J. Bentrem , Joseph Chao , Carlos Corvera , Prajnan Das , Crystal S. Denlinger , Peter C. Enzinger , Paul Fanta , Farhood Farjah , Hans Gerdes , Michael Gibson , Robert E. Glasgow , James A. Hayman , Steven Hochwald , Wayne L. Hofstetter , David H. Ilson , Dawn Jaroszewski , Kimberly L. Johung , Rajesh N. Keswani , Lawrence R. Kleinberg , Stephen Leong , Quan P. Ly , Kristina A. Matkowskyj , Michael McNamara , Mary F. Mulcahy , Ravi K. Paluri , Haeseong Park , Kyle A. Perry , Jose Pimiento , George A. Poultsides , Robert Roses , Vivian E. Strong , Georgia Wiesner , Christopher G. Willett , Cameron D. Wright , Nicole R. McMillian and Lenora A. Pluchino
Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
Read Full Article Here: https://doi.org/10.6004/jnccn.2019.0033